IBM•November 22, 2026 at 4:25 PM UTCSoftware & Services

IBM's 30% Drawdown Tests Software Rebuild as Long-Term Gains Mask Near-Term Pain

Read source article

What happened

IBM has fallen more than 30% from its June high, but a $1,000 investment from five years ago would still be worth over $2,200, masking the pain of recent buyers. The decline reflects investor skepticism after the July earnings stumble, where software growth disappointed and raised questions about the durability of the company's rebuild around software. The subsequent recovery was aided by delayed deal closures and acquisitions, not broad organic demand, leaving the market unconvinced. The next critical event is the January earnings report for the fourth quarter, which will show whether software growth can hold without one-off benefits. Until then, long-term holders sit on gains while newer investors face losses, creating a divided investor base.

Implication

The stock's decline toward the attractive entry zone of $225 increases its appeal, but the lack of organic software acceleration and weak consulting conversion argue against aggressive buying. The January earnings report will provide crucial data on whether delayed deal catch-up masked a softer trend. If software growth holds above 7% without slipped-deal explanations and Automation turns positive, the thesis strengthens. Conversely, if software growth decelerates and consulting remains weak, the bear case of $215 becomes more likely. Monitoring segment-level detail is essential, not headline numbers.

Thesis delta

The master report's WAIT rating and $225 attractive entry remain unchanged. The stock's further decline to around that level now warrants closer watch, but no new fundamental evidence has emerged to alter the core concerns about organic software growth and consulting conversion. The upcoming Q4 earnings in January are the next major catalyst to either confirm or reject the recovery thesis.

Confidence

High